Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.

Rebecca is Xconomy's co-founder. Follow @

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy
• Achaogen Eyes Sale in Bankruptcy Auction a Year After FDA Approval
• Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs